Skip to main content
Top

04-09-2023 | Cancer Immunotherapy | News

ESC 2023

Higher MACE risk with immune checkpoint inhibitors

MedNet.nl: Cancer patients treated with immune checkpoint inhibitors have an increased risk of major adverse cardiovascular events if they have a history of atherosclerotic cardiovascular disease or hypertension. Timely identification of this population is therefore essential.

Related topics